Keytruda Price Impact After 2026 Drug Tariff: How Much More for Cancer Treatment?
Keytruda could cost $22,500-$36,000 per month after the July 31, 2026 pharmaceutical tariff — a $54,000+ annual increase. Here's what cancer patients need to know.
Keytruda (pembrolizumab) is the world's bestselling cancer drug and one of the most important immunotherapy breakthroughs of the past decade. It's approved for over 20 cancer types — and it's made by Merck in Ireland. When the 100% pharmaceutical tariff takes effect July 31, 2026, Keytruda faces significant price pressure. For patients and caregivers, this raises urgent questions: will I still be able to afford my treatment? Will insurance still cover it? What alternatives exist? Here's the complete picture.
Keytruda Tariff Summary
| Fact | Value |
|---|---|
| Manufacturer | Merck |
| Manufacturing country | Ireland |
| Annex III company? | Yes — tariff effective July 31, 2026 |
| Current retail (monthly) | ~$18,000 |
| Current typical infusion center charge | $15,000-$20,000 per dose |
| Dosing | Every 3 or 6 weeks (varies by indication) |
| Projected retail after tariff (conservative) | ~$22,500 (+$4,500/mo) |
| Projected retail after tariff (likely) | ~$27,000 (+$9,000/mo) |
| Projected retail after tariff (worst) | ~$36,000 (+$18,000/mo) |
| Annual impact (likely) | +$108,000/year |
Why Keytruda Is Expensive
Keytruda's sticker price of ~$18,000/month is driven by:
- R&D recovery: Merck invested billions developing and studying pembrolizumab across 20+ indications
- Manufacturing complexity: Monoclonal antibody biologics require specialized cell culture and purification
- Patent exclusivity: No biosimilar competition until 2028 (expected)
- Inelastic demand: Patients with cancer cannot easily substitute or delay treatment
- Payer negotiation dynamics: US healthcare system structurally supports high specialty drug prices
The tariff adds 100% to the wholesale import cost, which is approximately 25-35% of retail. Even partial passthrough means substantial retail increases.
What You'll Actually Pay: Scenario Analysis
Unlike retail pharmacy drugs, Keytruda is administered in clinical settings (hospital infusion centers, oncology practices). Billing is handled through medical (not pharmacy) insurance — the Part B side for Medicare.
Scenario A: Medicare Part B + Supplement
- Part B covers 80% of approved amount
- Supplement (Medigap) covers the remaining 20%
- Patient out-of-pocket: $0 for covered services (after deductible)
Tariff impact on you: minimal. Medicare pays higher Part B rates; CMS absorbs the cost through the Part B fund. Your supplement continues to cover your share.
Scenario B: Commercial Insurance
- Plan covers infusion per policy terms
- Out-of-pocket max applies (typically $5,000-10,000/year for in-network)
- Once OOP max hit: remaining treatments in the plan year are free
Tariff impact on you: may accelerate reaching OOP max, but total annual OOP is capped.
Scenario C: High-Deductible Plan (HDHP)
- Full list price applies until deductible met
- With HSA, deductible of $3,000-8,000 typical
- Once met, coinsurance (typically 20%) applies until OOP max
Tariff impact on you: potentially significant. A single dose at $27,000 could consume your deductible entirely in one visit — but then OOP max protects you for the rest of the year.
Scenario D: Uninsured
Full cash price applies. At ~$18,000/month today, uninsured Keytruda is already unaffordable for most. Post-tariff at ~$27,000/month, it's effectively out of reach without patient assistance.
The good news: Merck's patient assistance program typically provides Keytruda FREE to qualifying uninsured patients. See below.
Annual Cost Scenarios
Keytruda is usually given for at least 12-24 months or until progression. Total cost:
| Timeline | Retail Annual Cost (today) | After-Tariff Annual (likely) | Difference |
|---|---|---|---|
| 12 months treatment | $216,000 | $324,000 | +$108,000 |
| 24 months treatment | $432,000 | $648,000 | +$216,000 |
For most patients, insurance (Medicare or commercial) absorbs the majority of this. But systemic cost increases affect premiums and reimbursement policies.
Merck Access Support and Patient Assistance
Merck has one of the best patient assistance programs in pharma:
Merck Access Program (commercial insurance)
- Co-pay assistance up to $25,000/year for eligible patients
- Usually reduces your out-of-pocket to $0-25 per infusion
- Available for commercial-insured patients only
Merck Patient Assistance Program (uninsured)
- Keytruda free for qualifying uninsured/under-insured patients
- Income requirement: up to 500% Federal Poverty Level (generous)
- Apply at keytruda.com or through your oncologist
Key message: If you or a family member is facing Keytruda treatment without insurance, do not accept "you can't afford it" — apply for the PAP immediately. Merck makes this program work for the vast majority of qualified applicants.
What About Biosimilars?
Biosimilar pembrolizumab is in development but not yet FDA-approved. Expected timeline:
- Patent expiration (core): 2028
- Biosimilar launches: 2028-2030
- Market penetration: gradual (oncology biosimilars face slower uptake than other classes)
If you're starting Keytruda treatment in 2026, biosimilars will not be available during your likely treatment duration. When they do arrive, biosimilar pembrolizumab will be exempt from the tariff (all biosimilars are exempt) and 20-50% cheaper.
Alternative Cancer Immunotherapies
Keytruda is an anti-PD-1 antibody. Other drugs in this class (and their tariff status):
| Drug | Manufacturer | Country | Tariff Status | Indications |
|---|---|---|---|---|
| Keytruda (pembrolizumab) | Merck | Ireland | Affected | Most common cancers |
| Opdivo (nivolumab) | BMS | Ireland | Affected | Similar to Keytruda |
| Tecentriq (atezolizumab) | Roche | Switzerland | Affected | Lung, bladder, liver |
| Imfinzi (durvalumab) | AstraZeneca | UK | Affected | Lung cancer |
| Libtayo (cemiplimab) | Regeneron | USA | Exempt | Skin cancers, lung cancer |
| Bavencio (avelumab) | Pfizer/Merck KGaA | USA | Exempt | Kidney, Merkel cell |
| Jemperli (dostarlimab) | GSK | UK | Affected | Endometrial, rectal |
Libtayo and Bavencio are US-made and exempt. They have more limited indications than Keytruda, but for overlapping cancers (particularly skin cancers and Merkel cell carcinoma), they may be viable alternatives.
Important: Switching immunotherapies is a major clinical decision. Keytruda has the most extensive evidence across cancer types. Don't switch based on cost alone — work with your oncologist.
Will Merck Make a Deal?
Merck is in negotiations with the administration. Potential deal outcomes:
- Pricing concession: Merck agrees to Most-Favored-Nation pricing on Keytruda (matching lowest developed-world price, which could significantly lower US retail)
- Manufacturing commitment: Merck builds or expands US manufacturing capacity for Keytruda
- Volume commitment: Negotiated procurement for Medicare and VA
- Tariff exemption: In exchange for pricing concessions
Merck has publicly signaled willingness to negotiate. A deal could significantly change Keytruda's 2026 price trajectory — in either direction (MFN pricing could lower US price; no deal keeps 100% tariff).
What Patients Should Do Now
If You're Currently on Keytruda
- Talk to your oncologist about treatment duration and cost management
- Contact Merck Access Program (1-855-257-3932) — they'll review your situation regardless of insurance
- Review your insurance benefits — check OOP max and Keytruda coverage tier
- Consider timing of infusions around your plan year — OOP max resets January 1
If You're Starting Keytruda
- Apply for Merck patient assistance early — don't wait for bills to arrive
- Confirm insurance coverage before first infusion
- Ask about clinical trial alternatives (some provide free drug during trial)
- Consider treatment centers that specialize in financial navigation
If You're Cancer-Free and Considering Future Coverage
- Evaluate your insurance coverage — does your plan cover Part B (medical) infusion drugs well?
- Understand OOP max — the most you'd pay for any year of treatment
- Consider Medicare Advantage vs original Medicare if near 65 — Part B coverage differs
Frequently Asked Questions
Is my Keytruda coverage at risk because of the tariff?
Extremely unlikely. Insurance coverage decisions are driven by FDA approval and medical necessity, not list price. Keytruda will remain covered by Medicare and virtually all commercial plans. Your cost-sharing may change, but coverage will not disappear.
Will I have to pay more out of pocket?
Depends on your plan. Medicare + Medigap: no change. Commercial with annual OOP max: no change beyond hitting OOP max (which you likely already do during a year of Keytruda treatment). HDHP: possibly more upfront but capped at OOP max. Uninsured: significant impact unless you qualify for PAP.
Can I delay treatment until after the tariff takes effect?
No. Cancer treatment timing is driven by medical necessity. Do not delay treatment for cost reasons. If cost is a barrier, call Merck Access Program immediately — they solve cost issues, not treatment delays.
What if my doctor recommends Keytruda but I can't afford it?
Contact Merck Access Program first. 90%+ of cost-motivated treatment refusals can be resolved through patient assistance. Second, ask your oncologist about clinical trials — many immunotherapy trials provide drug free during participation.
Are generic chemo drugs affected?
Generic chemotherapy drugs are exempt from the tariff (generics exempt). Older chemo regimens (cisplatin, paclitaxel, cyclophosphamide, etc.) are mostly available as generics and will not see tariff-driven price changes.
Conclusion
Keytruda faces a 100% tariff starting July 31, 2026, with retail projections of $22,500-36,000/month (up from ~$18,000). For insured patients, out-of-pocket max and Medicare coverage structures absorb most of the impact. For uninsured patients, Merck's patient assistance program is a lifeline that continues to work. The core message for cancer patients: the tariff changes Merck's economics, not your access to treatment. Stay in touch with your oncology care team and financial navigator. Check your specific Keytruda impact here.